Results 171 to 180 of about 7,494,393 (373)
RETRACTION: W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, “lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway,” Molecular Oncology 13, no. 10 (2019): 2246–2258, https://doi.org/10.1002/1878-0261.12553.
wiley +1 more source
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche+8 more
wiley +1 more source
Care of the Dying: The Doctor and Euthanasia [PDF]
The quality of the doctor patient relationship is central in this discussion of the euthanasia problem. Robert Rizzo, Ph.D., is Assistant Professor in the Department of Religious Studies at Canisius College, Buffalo, N.Y.
Rizzo, Robert, Yonder, Joseph
core +1 more source
Book Review: A Dictionary of Medical Ethics and Practice [PDF]
R V H Jones
openalex +1 more source
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner+6 more
wiley +1 more source
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul+11 more
wiley +1 more source